Tool for guidance: Evidence-based recommendations for managing febrile neutropenia

Korean Journal of Internal Medicine

Volumn 26, Issue 2, 2011, Pages 135-136

  Ullmann, Andrew J ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT;

CLINICAL PRACTICE; CONSENSUS DEVELOPMENT; DRUG APPROVAL; EDITORIAL; EVALUATION RESEARCH; EVIDENCE BASED MEDICINE; FEBRILE NEUTROPENIA; GOVERNMENT REGULATION; HUMAN; KOREA; MEDICAL CARE; MEDICAL EXPERT; NATIONAL HEALTH ORGANIZATION; PEER REVIEW; PRACTICE GUIDELINE;

ANTI-BACTERIAL AGENTS; ANTIBIOTIC PROPHYLAXIS; ANTIFUNGAL AGENTS; FEVER; HUMANS; NEUTROPENIA;

EID: 79959839890     PISSN: 12263303     EISSN: 20056648     Source Type: Journal    
DOI: 10.3904/kjim.2011.26.2.135     Document Type: Editorial

References (5)

1. Lee DG, Kim SH, Kim SY, et al. Evidence-based guidelines for empirical therapy of neutropenic fever in Korea. Korean J Intern Med 2011;26:220-252.
2. Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America. Clin Infect Dis 2011;52:427-431.
3. The periodic health examination. Canadian Task Force on the Periodic Health Examination. Can Med Assoc J 1979;121:1193-1254.
4. The AGREE Next Steps Consortium. The AGREE II Instrument [Internet]. The AGREE Research Trust, 2009 [cited 2011 May 15]. Available from: http://www.agreetrust.org.
5. Brozek JL, Akl EA, Compalati E, et al. Grading quality of evidence and strength of recommendations in clinical practice guidelines Part 3 of 3: the GRADE approach to developing recommendations. Allergy 2011;66:588-595.